Aplidin . Resultados de Fase III , ADMYRE TRIAL , In Relapsed / Refractory Multiple Myeloma . Date to be Presented December 9, 2017 at ASH Congress 2017 .

Today, at the Oral and Poster Abstracts of ASH17 , PharmaMar will be presenting the new advances in Relapsed/Refractory Multiple Myeloma. 5:30 PM-7: 30 PM (Atlanta, Georgia).

Presenter : Ivan Spicka .

CONCLUSIONS:

This phase III trial on plitidepsin in combination with DXM showed prolongation of both PFS and OS, with a remarkable duration of response.

These efficacy data, the reassuring safety profile and the novel mechanism of action of plitidepsin suggest that plitidepsin plus DXM can be considered as a new treatment option in patients with relapsed/refractory MM.